RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-06-12. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapycancerreceiving18 yearsstudy drug
  Phrases that lowered it: kgbodyplasmaparticipantsadult
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 10.9% (raises risk) · Sponsor's track record
• Collaborators: 9 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 44 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 13.3% (lowers risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Sponsor's past trials: 183 (lowers risk) · Sponsor's track record
• Primary purpose: supportive care (lowers risk) · Design
• Maximum age: 18 (raises risk) · Who can join
• Minimum age: 2.5 (lowers risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports before start: 48869 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 82.4% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC) NCT03219710 · started 2017 · scored riskier than 17% of active trials completed
• Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study NCT02129478 · started 2014 · scored riskier than 78% of active trials completed
• Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy NCT02097823 · started 2014 · scored riskier than 79% of active trials completed
• Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy NCT02116530 · started 2014 · scored riskier than 58% of active trials completed
• Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV NCT05805800 · started 2023 · scored riskier than 44% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.